This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-7 (canceled)

8. (currently amended) A pharmaceutical composition for stimulating sexual response in a mammal, comprising a peptide and a pharmaceutically acceptable aqueous carrier, wherein said peptide is a free acid or pharmaceutically acceptable salt thereof comprising ~~a~~ the sequence ~~selected from the group consisting of His-Phe-Arg-Trp (SEQ ID NO:1), His-D-Phe-Arg-Trp, homologs of His-Phe-Arg-Trp (SEQ ID NO:1) and homologs of His-D-Phe-Arg-Trp~~ Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH.

9. (currently amended) The pharamceutical composition of claim 8, wherein said peptide is ~~a cyclic peptide~~ cyclicized through the side chains of Asp and Lys without introduction of an additional molecular unit.

10. (currently amended) The pharmaceutical composition of claim 8, wherein said peptide has ~~a terminal carboxyl group~~ an amino terminus acetylated amino group.

11. (original) The pharmaceutical composition of claim 8, wherein the peptide consists of the sequence Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH.

12. (currently amended) A method for stimulating sexual response in a mammal, comprising administering a pharmaceutically sufficient amount of a composition comprising a peptide or pharmaceutically acceptable salt thereof of the formula Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH to stimulate a sexual response.

13. (original) The method of claim 12, wherein the mammal is a male.

14. (original) The method of claim 12, wherein the mammal is a female.

15. (original) The method of claim 12, wherein the pharmaceutically sufficient amount is at a dose level that does not induce emesis or other deleterious side effects.

16. (original) The method of claim of claim 12, wherein the composition further comprises a pharmaceutically acceptable carrier.

17. (original) The method of claim 12, wherein administering comprises administering by a method of administration selected from the group consisting of administration by injection, administration through mucous membranes, buccal administration, oral administration, dermal administration, inhalation administration and nasal administration.

18. (original) The method of claim 17, wherein administering comprises nasal administration of a metered amount of a formulation comprising an aqueous buffer.

19. (original) The method of claim 18, wherein the aqueous buffer is a member selected from the group consisting of saline and citrate buffer.

Claims 20-27 (canceled)

28. (new) A peptide or pharmaceutically acceptable salt thereof consisting of substantially pure Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH.

29. (new) A peptide or pharmaceutically acceptable salt thereof consisting of isolated peptide of the sequence Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH.

30. (new) A pharmaceutical kit, comprising the pharmaceutical composition of claim 8 disposed in a nasal administration device.

31. (new) The pharmaceutical kit of claim 30 wherein the nasal administration device is a metered dose nasal administration device.

32. (new) The pharmaceutical kit of claim 31 wherein the metered dose nasal administration device dispenses a metered spray volume of approximately 100 µL.

33. (new) The pharmaceutical kit of claim 30 wherein the pharmaceutically acceptable salt is an acetate salt.

34. (new) A manufactured peptide of the formula: